Parmax Pharma (BOM:540359) Operating Margin %: -54.35% (As of Mar. 2026)


BOM:540359 Parmax Pharma Ltd BOM:540359
45 GF Score
Price ₹75.08
GF Value ₹25.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Parmax Pharma Operating Margin %?

Parmax Pharma BOM:540359 +2.00% 45 Operating Margin % is -54.35% as of Mar. 2026. GuruFocus rates BOM:540359 with a GF Score™ of 45/100 and a GF Value™ of ₹25.70 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, Parmax Pharma ranks worse than 87.33% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Parmax Pharma's Operating Income for the three months ended in Mar. 2026 was ₹-18.0 Mil. Parmax Pharma's Revenue for the three months ended in Mar. 2026 was ₹33.1 Mil. Therefore, Parmax Pharma's Operating Margin % for the quarter that ended in Mar. 2026 was -54.35%.

The historical rank and industry rank for Parmax Pharma's Operating Margin % or its related term are showing as below:

BOM:540359' s Operating Margin % Range Over the Past 10 Years
Min: -42.07   Med: 0.69   Max: 7.55
Current: -37.99


BOM:540359's Operating Margin % is ranked worse than
87.33% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs BOM:540359: -37.99

Parmax Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Parmax Pharma's Operating Income for the three months ended in Mar. 2026 was ₹-18.0 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-46.0 Mil.


Parmax Pharma  (BOM:540359) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Parmax Pharma Operating Margin % Related Terms


Parmax Pharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for Parmax Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma Operating Margin % Chart

Parmax Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.67 5.21 -42.07 -2.76 -38.41

Parmax Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.05 -25.28 -72.91 -10.72 -54.35

BOM:540359 vs ZTS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parmax Pharma Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Parmax Pharma's Operating Margin % falls into.


BOM:540359
45GF Score
Parmax Pharma Ltd BOM:540359
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parmax Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Parmax Pharma's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=-46.526 / 121.116
=-38.41 %

Parmax Pharma's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-18.006 / 33.127
=-54.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -54.35% mean?
Parmax Pharma (BOM:540359) has a Operating Margin % of -54.35% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Parmax Pharma and its competitors. According to the industry distribution chart, Parmax Pharma ranks #834 out of 955 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is Parmax Pharma's Operating Margin % too high?
Parmax Pharma's current Operating Margin % is -54.35%. Based on the distribution chart, Parmax Pharma ranks #834 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Parmax Pharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #834 out of 955 companies for Operating Margin %. This places Parmax Pharma in the lower half of its industry. The industry median Operating Margin % is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current Operating Margin % is -54.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹25.70, compared to a current price of ₹75.08 — trading 192.1% above its estimated fair value. The current Operating Margin % is -54.35%. Parmax Pharma's overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current Operating Margin % is -54.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Parmax Pharma (BOM:540359) Overvalued in 2026?

Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued. The current stock price of ₹75.08 is trading 192.1% above its estimated GF Value™ of ₹25.70. GuruFocus considers Parmax Pharma to be Significantly Overvalued.

Key valuation signals for BOM:540359:

  • Operating Margin %: -54.35%
  • GF Value™: ₹25.70 vs. price of ₹75.08 (192.1% above fair value)
  • GF Score™: 45/100 with 8 warning signs

No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Parmax Pharma Business Description

Address Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its Core Segments: Anti-infectives, Analgesics & anti-inflammatory, Cardiovascular APIs, General oral formulations (tablets, capsules) Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.
45GF Score

Get the complete analysis for BOM:540359

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹75.08
Price
₹25.70
GF Value